Journal
ALZHEIMERS & DEMENTIA
Volume 13, Issue 3, Pages 274-284Publisher
WILEY
DOI: 10.1016/j.jalz.2016.09.008
Keywords
Alzheiiner's disease; Biomarkers; CSF; Diagnosis; GRADE; Recommendations
Categories
Funding
- Denmark: Innovation Fund Denmark [0603-00470B]
- Finland: Academy of Finland [263193]
- Germany: BIOMARKAPD [01ED1203F]
- Germany: SOPHIA [01ED1202A]
- Italy: Ministero della Salute [JPND N 469/2012]
- Netherlands: ZonMW project [629000002]
- Poland: The National Center for Research and Development [3/BIO-MARKAPD/JPND/2012]
- Poland: Leading National Research Center (KNOW)
- Poland: Medical University of Bialystok, Bialystok, Poland
- Portugal: Foundation for Science and Technology-FCT [JPND/0005/2011]
- Slovenia: Slovenian Research Agency [A3-0001]
- Spain: Institute de Salud Carlos III [PI11/03023]
- Sweden: Swedish Research Council [529-2012-16, C0001401]
- Turkey: TUBITAK [112S360]
- German Federal Ministry of Education and Research [FTLDc O1GI1007A]
- KKMS
- MND-Net [01GM1103A]
- EU [NADINE 246513, FAIR-PARK II 633190]
- Foundation of the State Baden-Wurttenberg [D.3830]
- BIU
- Sigrid Juselius Foundation (JR) Swedish Research Council [05817]
- University of Antwerp Research Fund
- Alzheimer Research Foundation (SAO-FRA)
- Agency for Innovation by Science and Technology (IWT)
- Research Foundation Flanders (FWO)
- Belgian Science Policy Office Interuniversity Attraction Poles (IAP) program (BELSPO)
- Flemish Government initiated Methusalem excellence grant (EWI)
- Flanders Impulse Program on Networks for Dementia Research (VIND)
- Fundação para a Ciência e a Tecnologia [JPND/0005/2011] Funding Source: FCT
- Academy of Finland (AKA) [263193, 263193] Funding Source: Academy of Finland (AKA)
Ask authors/readers for more resources
This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebiospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support 4 recommendation to use CSF ADbiomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD bioniarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available